[1] ZHOU J,LIU J,GAO Y,et al. MiRNA-based potential biomarkers and new molecular insights in ulcerative colitis[J].Front Pharmacol,2021,12(2):757-776.
[2] DANIAO A,QUEIROZ N. Medical therapy in chronic refractory ulcerative colitis: when enough is enough[J].Clin Colon Rectal Surg,2022,35(1): 32-43.
[3] LI C, WANG J,MA R, et al.Natural-derived alkaloids exhibit great potential in the treatment of ulcerative colitis[J].Pharmacol Res,2022,175(12): 105-111.
[4] NAGHDALIPOUR M,MORADI N,FADAEI R,et al. Alteration of miR-21,miR-433 and miR-590 tissue expression related to the TGF-β signaling pathway in ulcerative colitis patients[J].Arch Physiol Biochem,2022,128(5): 1170-1174.
[20] YU J, WANG S, YUAN H,et al.Expression of th17/treg cells in peripheral blood and related cytokines of patients with ulcerative colitis of different syndrome types and correlation with the disease[J]. Evid Based Complement Alternat Med,2021,42(4):460-472.
[21] RUFINO MN, ALDA COSTA,et al. Synbiotics improve clinical indicators of ulcerative colitis: systematic review with meta-analysis[J].Nutr Rev,2022,80(2):157-164.
[22] HU LH, LIU JY, YIN JB. Eriodictyol attenuates TNBS-induced ulcerative colitis through repressing TLR4/NF-kB signaling pathway in rats[J]. Kaohsiung J Med Sci,2021,37(9):812-818.
[23] CUI M,PANG G,ZHANG T.Optotheranostic Nanosystem with Phone Visual Diagnosis and Optogenetic Microbial Therapy for Ulcerative Colitis At-Home Care[J]. ACS Nano,2021,15(4):7040-7052.